US2024026023A1PendingUtilityA1

OPTIMIZED Fc VARIANTS

80
Assignee: XENCOR INCPriority: Jul 20, 2004Filed: Aug 25, 2023Published: Jan 25, 2024
Est. expiryJul 20, 2024(expired)· nominal 20-yr term from priority
Inventors:Gregory Alan LazarWei DangJohn DesjarlaisSher Bahadur KarkiOmid VafaRobert HayesJost Vielmetter
C07K 16/2887C07K 16/32C07K 16/2863C07K 16/2893A61K 47/68C07K 16/00C07K 16/18C07K 16/2896C07K 16/30C07K 2317/524C07K 2317/73C07K 2317/71C07K 2317/732C07K 2317/41C07K 2317/72C07K 2317/734A61K 2039/505C07K 2317/24C07K 2317/31C07K 2317/34C07K 2317/40C07K 2317/52C07K 2317/56C07K 2317/64C07K 2317/77C07K 2317/92C07K 2317/94
80
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.

Claims

exact text as granted — not AI-modified
1 . A protein comprising an Fc variant of a human IgG1 Fc polypeptide, wherein said Fc variant comprises an amino acid modification in the Fc region of said parent Fc polypeptide at position 243, wherein said protein exhibits altered binding affinity to an Fcγ receptor (FcγR) as compared to a parent polypeptide, wherein numbering is according to the EU index. 
     
     
         2 .- 8 . (canceled)

Join the waitlist — get patent alerts

Track US2024026023A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.